Closed Oversubscribed CAN$10 Million Private Placement
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.
TORONTO, ON / ACCESSWIRE / January 4, 2021 / Novamind Inc. (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic-assisted psychotherapy, is pleased to announce that its common shares will commence trading on the Canadian Securities Exchange under the symbol “NM” tomorrow, January 5, 2021. “Over the last 18 months, we have developed an industry-leading network of mental health clinics and clinical research sites focused on psychedelic medicine,” commented Yaron Conforti, CEO and Director of Novamind. “Our public listing, along with our oversubscribed CAN$10 million financing, position Novamind to rapidly expand its base of operations organically and through strategic acquisitions.” To view Novamind’s corporate presentation and read recent press releases, please click here.
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.
Yaron Conforti, CEO and Director
Bill Mitoulas, Investor Relations
Telephone: +1 (647) 953 9512
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.